Immunogenic Composition with Electrostatic Dendritic Cell Targeting

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current immunogenic compositions fail to effectively target dendritic cells, which are crucial for generating an immune response, as they do not utilize electrostatic interactions between antigens and dendritic cell ligands, limiting their ability to induce robust antibody and cell-mediated responses, especially in viral infections and cancer.

Innovation Solution

Development of immunogenic compositions that electrostatically associate a polypeptide antigen with a dendritic cell targeting component, where the antigen has a negatively charged region and the targeting component has a positively charged group with branched peptides covalently attached to a Toll-like receptor ligand, such as Pam2Cys, facilitating targeted delivery to dendritic cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional immunogenic compositions are used, then the composition structure is simple, but the ability to target dendritic cells is insufficient

Engineering Contradiction:
Improvetargeting ability to dendritic cellsVSAvoidcomposition structure
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent combines an antigen with a dendritic cell targeting component to form an immunogenic composition. The targeting component includes a cationic peptide sequence that electrostatically interacts with the negatively charged antigen, creating a composite structure that simultaneously provides antigenicity and dendritic cell targeting capability.

Inventive Principle:
Principle #5Merging (Combining)

Solution Approach 2:

The patent utilizes electrostatic charge parameters to achieve targeted delivery. The cationic peptide sequence (with positive charge) interacts with the negatively charged antigen through electrostatic attraction, creating a charge-based targeting mechanism that enhances dendritic cell uptake without requiring complex structural modifications.

Inventive Principle:
Principle #35Parameter changes

2Reliability

If electrostatic association is used between antigen and dendritic cell targeting component, then the immune response is enhanced, but the interaction mechanism becomes more complex

Engineering Contradiction:
Improveimmune response strengthVSAvoidinteraction mechanism
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent replaces complex mechanical or chemical conjugation methods with electrostatic interaction mechanisms. The cationic peptide sequence naturally interacts with the negatively charged antigen through electrostatic attraction, providing a simpler and more versatile binding mechanism that enhances immune response without requiring complex molecular conjugation.

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

3Device complexity

If the antigen is associated with dendritic cell targeting component by electrostatic interaction only, then the composition is simpler, but the stability of association may be reduced

Engineering Contradiction:
Improveassociation mechanismVSAvoidantigen-targeting component association
Core Design Contradiction:
Device complexityVSStability of the object's composition

Solution Approach 1:

The patent optimizes the electrostatic interaction by carefully selecting the cationic peptide sequence and its charge density. The peptide sequence (with multiple basic amino acids) provides sufficient positive charge to maintain stable association with the negatively charged antigen through electrostatic attraction, while keeping the overall composition relatively simple.

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The electrostatic association enhances the immunogenicity of antigens by eliciting strong antibody and cell-mediated responses, as demonstrated by increased antibody titers and activated CD8+ T cells, indicating improved immune response efficacy.

Implementation Method 1

the polypeptide antigen comprises a negatively charged region and wherein the dendritic cell targeting component comprises a positively charged group... wherein the negatively charged region of antigen is electrostatically associated with the positively charged group of the dendritic cell targeting component

Methodology Applied
Scientific EffectElectrostatic interaction: Electrostatics

Data Source

PatentEP2946789B1Immunogenic composition and uses thereof
Publication Date: 2018.02.28 ENA THERAPEUTICS PTY LTD
  • EP2946789B1 patent drawingFigure 1A~1B
  • EP2946789B1 patent drawingFigure 2
  • EP2946789B1 patent drawingFigure 3

AI summary

The present invention provides an immunogenic composition comprising an antigen and a dendritic cell targeting component. A charged group is covalently attached to a dendritic cell ligand and is electrostatically associated with the dendritic cell targeting component.